BioXcel Therapeutics's Earnings Outlook
Portfolio Pulse from Benzinga Insights
BioXcel Therapeutics (NASDAQ:BTAI) is scheduled to release its quarterly earnings report on March 12, 2024, with an expected EPS of $-0.91. Despite past earnings misses, the company's stock price has shown mixed reactions, with a significant 85.15% decline over the last year. Investors are keen on the upcoming guidance for future growth.
March 11, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BioXcel Therapeutics is expected to report an EPS of $-0.91 for the upcoming quarter. Historical performance shows mixed reactions to earnings reports, with a notable overall decline in stock price over the past year.
The expected EPS of $-0.91 sets a cautious tone for BioXcel Therapeutics' upcoming earnings report. Historical data shows that the company's stock price can react variably to earnings reports and guidance. Given the significant decline in stock price over the past year, the short-term impact is uncertain but leans towards neutral as investors may have already adjusted expectations based on past performance and the overall downward trend.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100